Efficacy and Safety of Ertugliflozin across Racial Groups in Patients with Type 2 Diabetes Mellitus (T2DM)

医学 安慰剂 内科学 血压 糖尿病 不利影响 血红蛋白 种族群体 内分泌学 种族(生物学) 生物 植物 病理 替代医学
作者
Jie Liu,Lisa Tarasenko,Annpey Pong,Susan Huyck,Larry Wu,James P. Mancuso,Steven G. Terra,Brett Lauring
出处
期刊:Diabetes [American Diabetes Association]
卷期号:67 (Supplement_1) 被引量:1
标识
DOI:10.2337/db18-1132-p
摘要

Ertugliflozin (ERTU) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of T2DM. Pharmacokinetic analysis indicates ERTU plasma exposure is not affected by race. The efficacy and safety of ERTU by race was assessed in pooled analyses from 3 randomized, double-blind, placebo (PBO)-controlled, Phase 3 trials. Patients received ERTU 5 mg, 15 mg or PBO for 26 weeks. Least-squares (LS) means for change from baseline to Week 26 were calculated for hemoglobin A1C (A1C), body weight (BW) and systolic blood pressure (SBP). General and prespecified adverse events (AEs) were evaluated. The analysis included 1544 patients (white 73%; black 7%; asian 15%; other 5%). Baseline demographics and characteristics were generally similar across treatment groups and racial groups, except lower mean BW and BMI in Asians. No notable differences in A1C, BW and SBP reductions were observed across racial groups (Table 1), except for a greater SBP reduction observed in Blacks. Across racial groups there were no notable differences in general AEs with ERTU vs. PBO. An increase in genital mycotic infections was seen with ERTU vs. PBO across all racial groups. Precision of between-treatment effects was limited in Blacks, Asians and Others due to small group size. ERTU efficacy and safety was generally similar across racial groups although a greater reduction in SBP was observed in Blacks.Table 1. Least-squares Mean Change (Placebo-corrected) in A1C, Body Weight and SBP from Baseline to Week 26 by Racial Group (Excluding Rescue Approach)RaceErtugliflozin Dose (N)*δA1C (%) LS mean (95% CI)δBody Weight (kg) LS mean (95% CI)δSBP (mmHg) LS mean (95% CI)Overall5 mg (519)-0.8 (-0.9, -0.7)-1.8 (-2.2, -1.4)-3.4 (-4.8, -2.0)15 mg (510)-0.9 (-1.0, -0.8)-1.8 (-2.2, -1.4)-3.5 (-4.9, -2.0)White5 mg (382)-0.8 (-1.0, -0.7)-1.9 (-2.3, -1.4)-3.3 (-4.9, -1.6)15 mg (374)-1.0 (-1.1, -0.8)-1.7 (-2.2, -1.2)-3.5 (-5.1, -1.8)Black5 mg (34)-0.7 (-1.2, -0.2)-1.1 (-2.8, 0.6)-9.5 (-16.0, -2.9)15 mg (37)-0.8 (-1.3, -0.3)-2.2 (-3.9, -0.6)-8.1 (-14.6, -1.7)Asian5 mg ( 77)-0.8 (-1.1, -0.5)-1.9 (-2.6, -1.1)-1.8 (-5.3, 1.8)15 mg (77)-1.0 (-1.3, -0.8)-2.1 (-2.8, -1.4)-1.9 (-5.4, 1.7)Other5 mg (26)-0.3 (-0.9, 0.3)-1.7 (-3.2, -0.2)-3.5 (-11.3, 4.4)15 mg (22)-0.9 (-1.5, -0.3)-1.5 (-3.0, 0.1)-4.4 (-12.8, 3.9)CI, confidence interval; LS, Least Squares *N is the number of randomized patients who took at least one dose of study medication. The LS Means for Change from Baseline to Week 26 were estimated from a constrained longitudinal data analysis model. Disclosure J. Liu: None. L. Tarasenko: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc.. A. Pong: None. S. Huyck: Employee; Self; Merck & Co., Inc.. L. Wu: None. J.P. Mancuso: Employee; Self; Pfizer Inc.. Stock/Shareholder; Self; Pfizer Inc.. Employee; Spouse/Partner; Pfizer Inc.. Stock/Shareholder; Spouse/Partner; Pfizer Inc. S. Terra: Employee; Self; Pfizer Inc. B. Lauring: Employee; Self; Merck & Co., Inc..
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香菜完成签到 ,获得积分10
刚刚
Jeremy完成签到 ,获得积分10
4秒前
回首不再是少年完成签到,获得积分0
11秒前
又又完成签到,获得积分10
14秒前
斯文败类应助科研小兵兵采纳,获得10
17秒前
科研小郭完成签到,获得积分10
18秒前
安安滴滴完成签到 ,获得积分10
19秒前
王磊完成签到 ,获得积分10
25秒前
哈哈哈哈嘻嘻嘻完成签到 ,获得积分10
31秒前
48秒前
TTTHANKS发布了新的文献求助10
51秒前
theo完成签到 ,获得积分10
1分钟前
知行合一完成签到 ,获得积分10
1分钟前
迈克老狼完成签到 ,获得积分10
1分钟前
666完成签到 ,获得积分10
1分钟前
linwf完成签到 ,获得积分10
1分钟前
Singularity应助TTTHANKS采纳,获得10
1分钟前
笨笨忘幽完成签到,获得积分10
1分钟前
叶痕TNT完成签到 ,获得积分10
1分钟前
柒月完成签到 ,获得积分10
1分钟前
自信放光芒~完成签到 ,获得积分10
1分钟前
奶糖喵完成签到 ,获得积分10
1分钟前
Hank完成签到 ,获得积分10
1分钟前
氨气完成签到 ,获得积分0
1分钟前
沙子完成签到 ,获得积分0
1分钟前
fang完成签到,获得积分10
1分钟前
阿玖完成签到 ,获得积分10
1分钟前
不知道完成签到,获得积分10
2分钟前
一禅完成签到 ,获得积分10
2分钟前
芝诺的乌龟完成签到 ,获得积分0
2分钟前
mrwang完成签到 ,获得积分10
2分钟前
lingshan完成签到 ,获得积分10
2分钟前
科研小兵兵完成签到,获得积分10
2分钟前
2分钟前
成就的孤晴完成签到 ,获得积分10
2分钟前
郝君颖完成签到 ,获得积分10
2分钟前
2分钟前
CLTTT完成签到,获得积分10
2分钟前
mathmotive完成签到,获得积分10
2分钟前
吃小孩的妖怪完成签到 ,获得积分10
2分钟前
高分求助中
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Gerard de Lairesse : an artist between stage and studio 500
Digging and Dealing in Eighteenth-Century Rome 500
Queer Politics in Times of New Authoritarianisms: Popular Culture in South Asia 500
Livre et militantisme : La Cité éditeur 1958-1967 500
Retention of title in secured transactions law from a creditor's perspective: A comparative analysis of selected (non-)functional approaches 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3063230
求助须知:如何正确求助?哪些是违规求助? 2717989
关于积分的说明 7456754
捐赠科研通 2364300
什么是DOI,文献DOI怎么找? 1253400
科研通“疑难数据库(出版商)”最低求助积分说明 608585
版权声明 596606